Get the Stockscreener App
4.35
1.81%
-0.08
After Hours:
4.35
Karyopharm Therapeutics Inc stock is traded at $4.35, with a volume of 48,391.
It is down -1.81% in the last 24 hours and down -3.12% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$4.43
Open:
$4.42
24h Volume:
48,391
Relative Volume:
0.42
Market Cap:
$37.58M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-3.4252
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
+12.99%
1M Performance:
-3.12%
6M Performance:
-58.57%
1Y Performance:
-69.80%
1-Day Range:
$4.35
$4.60
1-Week Range:
$3.85
$4.91
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
4.35 | 41.99M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
What drives Karyopharm Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia
Karyopharm Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - PrintWeekIndia
What analysts say about Karyopharm Therapeutics Inc. stockUnprecedented market success - Autocar Professional
How high can Karyopharm Therapeutics Inc. stock price go in 2025High-yield market plays - jammulinksnews.com
Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com
Is Karyopharm Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser
HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN
H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser
Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals
HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest
Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa
Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN
Karyopharm's Freefall: What's Driving the Collapse? - AInvest
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
| Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
| Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
| Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
| Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
| Paulson Richard A. | President and CEO |
Feb 04 '25 |
Sale |
0.65 |
4,099 |
2,664 |
1,120,158 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):